Histological Outcomes and JAK-STAT Signalling in Ulcerative Colitis Patients Treated with Tofacitinib.
Sara van GennepIvan C N FungDjuna C de JongRishand K RamkisoenEsmé ClasquinJitteke de JongLeonie C S de VriesWouter J de JongeKrisztina B GecseMark LöwenbergJohn C WoolcottAart MookhoekGeert R A M D'HaensPublished in: Journal of Crohn's & colitis (2024)
Tofacitinib treatment resulted in histological improvement in the majority of UC patients and in a substantial decrease of STAT1, STAT3, and STAT5 expression. HEMI was associated with more profound suppression of STAT1.
Keyphrases
- ulcerative colitis
- cell proliferation
- rheumatoid arthritis
- end stage renal disease
- poor prognosis
- newly diagnosed
- chronic kidney disease
- intellectual disability
- peritoneal dialysis
- metabolic syndrome
- autism spectrum disorder
- patient reported outcomes
- adipose tissue
- insulin resistance
- skeletal muscle
- replacement therapy